If you are uncertain about the appropriate angle, consult your healthcare provider or diabetes care and education specialist (CDCES)
It should not be marketed that way
Therefore, they share the same half-life of approximately seven days
Tirzepatide works as a dual agonist targeting GLP-1 and GIP receptors while retatrutide works on glucagon receptors as a third mechanism
Obesity and metabolic disease carry particular health burdens for men, including increased risk of type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, and hypogonadism (low testosterone)
The lack of affordable, accessible GLP-1 medications will continue to obfuscate future large cohort analysis of patients using them due to the disrupting influences of social determinants of health